Arcellx, Inc. and Kite, a Gilead Company, have expanded the scope of their existing collaboration for CART-ddBCMA to include lymphomas. Kite exercised its option to negotiate a license for Arcellx’s ARC-SparX program, ACLX-001, in multiple myeloma, which is comprised of ARC-T cells and SparX proteins that target BCMA. CART-ddBCMA uses D-Domain (DD), which is designed to improve target specificity while enhancing binding affinity, in lieu of a scFv antigen recognition motif.  Arcellx ...